Shots:
Cullinan to receive $275M up front, ~ $130M in regulatory-based milestones & the transaction is expected to close in Q2’22. Additionally, both companies will equally share 50% of the profits for the future clinical development of CLN-081/TAS6417 in the US
Under the agreement with Taiho, Cullinan gets global rights to CLN-081/TAS6417 outside Japan & obtains the option to co-commercialize & co-develop CLN-081/TAS6417 (TK inhibitor)
Taiho retains exclusive rights globally to CLN-081/TAS6417 in territories outside US & China. CLN-081/TAS6417 is being studied in the P-I/IIa study for NSCLC with exon 20 insertion mutation with an expected initiation of the study in H2’22
Ref: Globenewswire | Image: Taiho
